Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Insero enters licensing deals to produce Huperzine
Huperzine, sourced from a naturally occurring botanical extract, is used as a treatment for memory loss and other disorders. The company also licensed key patents from Harvard University
Huperzine, sourced from a naturally occurring botanical extract, is used as a treatment for memory loss and other disorders. The company also licensed key patents from Harvard University
This new warehouse facility will distribute high purity specialty organic chemicals throughout the eastern US. The TCI America distribution center is expected to provide 10 living wage jobs
The companies have collaborated to construct custom, synthetic, double-stranded nucleic acids up to 5 kb. As per the agreement, IDT will use oligonucleotide manufacturing expertise, including gBlocks Gene
Imetelstat is a potent and specific inhibitor of telomerase, which is required for tumor cell immortality and growth. The open label, multi-center, randomized Phase 2 trial (B014) study
Expanded access refers to the use of an investigational drug, under certain circumstances, to treat patients with a serious disease or condition who cannot participate in a controlled
The development of an oral formulation for use in humans aims to maximize the amount of an orally administered drug that is absorbed and then circulates in the
Synera is approved for use on intact skin to provide local dermal analgesia for superficial venous access and superficial dermatological procedures such as excision, electrodessication and shave biopsy
Asparec is a recombinant, pegylated Erwinia chrysanthemi-derived asparaginase, and is currently in Phase I development for the treatment of ALL patients with hypersensitivity to standard-of-care. As per the
Earlier pre-clinical and clinical data suggested that VAL-083 may be active against a range of tumor types, including GBM. DelMar Pharma president and CEO Jeffrey Bacha said the
The review has been completed and the FDA has notified the company to proceed with the studies related to IND. The company is expected to initiate Phase III